Saturday, October 31, 2026

Intel Stock Is 3% Down As Session Comes To An End Today

ViaNews Editorial Team

December 21, 2020

Intel Stock Is 3% Down As Session Comes To An End Today

Shares of Intel slid 3.04% to $46.01 at 15:36 EST on Monday, after two consecutive sessions in a row of losses. The Nasdaq Stock Market is falling 0.28% to $12,720.50, following yesterday's downward trend, This seems, up to now, a somewhat negative trend trading session today.

Intel's last close was $47.46, 50.60% under its 52-week high of $69.29.

News about Intel today

Intel investigating solarwinds hack risk, sees no impact. According to today's article on Bloomberg Quint, "Intel Corp., the world's largest chipmaker, said it's investigating whether it was a victim of the SolarWinds Corp. hack that has roiled the U.S. government and private sector."

Intel's Sales

Intel's sales growth is a negative 13.7% for the current quarter and a decline by 17.6% for the next. The company's growth estimates for the present quarter and the next is a negative 27.6% and a negative 35.2%, respectively.

Intel's Revenue

Year-on-year quarterly revenue growth declined by 4.5%, now sitting on 78.1B for the twelve trailing months.

Intel's Stock Yearly Top and Bottom Value

Intel's stock is valued at $46.01 at 15:36 EST, way below its 52-week high of $69.29 and higher than its 52-week low of $43.61.

Intel's Moving Average

Intel's value is under its 50-day moving average of $47.69 and way under its 200-day moving average of $51.96.

Previous days news about Intel

Intel stock drops after report of Microsoft developing its own chips. According to MarketWatch on Fri Dec 18, "Intel shares closed Friday down 6.3% at $47.46, while shares of Advanced Micro Devices Inc. , which also makes CPUs, closed down 1% at $95.92. ", " In November, Apple Inc. , which had been relying on Intel chips until recently, released computers using in-house designed chips."

: Intel stock drops 6% after report of Microsoft developing its own chips. According to MarketWatch on Fri Dec 18, "Intel Corp. shares closed down Friday following a report that Microsoft Corp. was developing in-house chips for its servers and Surface PCs. ", "Intel shares closed Friday down 6.3% at $47.46, while shares of Advanced Micro Devices Inc. , which also makes CPUs, closed down 1% at $95.92. "

Chip giants Intel and NVIDIA face new threats from Amazon to google. According to The Wall Street Journal on Sun Dec 20, "Chip making has long been ruled by big manufacturers and design houses such as Intel Corp. , Advanced Micro Devices Inc. and graphics-chip maker Nvidia Corp. Now Amazon.com Inc., Microsoft Corp. and Google are getting into the game in the hunt for improved performance and lower costs, shifting the balance of power in the industry and pushing traditional chip makers to respond by building more specialized chips for major customers."

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com